| Literature DB >> 34139255 |
Alexandros Marios Sofias1, Federica De Lorenzi2, Quim Peña2, Armin Azadkhah Shalmani2, Mihael Vucur3, Jiong-Wei Wang4, Fabian Kiessling2, Yang Shi2, Lorena Consolino5, Gert Storm6, Twan Lammers7.
Abstract
Fibrosis is a common denominator in many pathologies and crucially affects disease progression, drug delivery efficiency and therapy outcome. We here summarize therapeutic and diagnostic strategies for fibrosis targeting in atherosclerosis and cardiac disease, cancer, diabetes, liver diseases and viral infections. We address various anti-fibrotic targets, ranging from cells and genes to metabolites and proteins, primarily focusing on fibrosis-promoting features that are conserved among the different diseases. We discuss how anti-fibrotic therapies have progressed over the years, and how nanomedicine formulations can potentiate anti-fibrotic treatment efficacy. From a diagnostic point of view, we discuss how medical imaging can be employed to facilitate the diagnosis, staging and treatment monitoring of fibrotic disorders. Altogether, this comprehensive overview serves as a basis for developing individualized and improved treatment strategies for patients suffering from fibrosis-associated pathologies.Entities:
Keywords: Atherosclerosis; Cancer; Cardiovascular disease; Diabetes; Drug targeting; Fibrosis; Imaging; Liver; Nanomedicine; Viral infection
Mesh:
Year: 2021 PMID: 34139255 PMCID: PMC7611899 DOI: 10.1016/j.addr.2021.113831
Source DB: PubMed Journal: Adv Drug Deliv Rev ISSN: 0169-409X Impact factor: 15.470